Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray.
Diffuse large B-cell lymphoma (DLBCL) can be divided into prognostically important subgroups with germinal center B-cell-like (GCB), activated B-cell-like (ABC), and type 3 gene expression profiles using a cDNA microarray. Tissue microarray (TMA) blocks were created from 152 cases of DLBCL, 142 of w...
| Main Authors: | , , , , , , , , , , , , , , , , , , , |
|---|---|
| 格式: | Journal article |
| 語言: | English |
| 出版: |
2004
|
| _version_ | 1826277092006821888 |
|---|---|
| author | Hans, C Weisenburger, D Greiner, T Gascoyne, R Delabie, J Ott, G Müller-Hermelink, H Campo, E Braziel, R Jaffe, E Pan, Z Farinha, P Smith, L Falini, B Banham, A Rosenwald, A Staudt, L Connors, J Armitage, J Chan, W |
| author_facet | Hans, C Weisenburger, D Greiner, T Gascoyne, R Delabie, J Ott, G Müller-Hermelink, H Campo, E Braziel, R Jaffe, E Pan, Z Farinha, P Smith, L Falini, B Banham, A Rosenwald, A Staudt, L Connors, J Armitage, J Chan, W |
| author_sort | Hans, C |
| collection | OXFORD |
| description | Diffuse large B-cell lymphoma (DLBCL) can be divided into prognostically important subgroups with germinal center B-cell-like (GCB), activated B-cell-like (ABC), and type 3 gene expression profiles using a cDNA microarray. Tissue microarray (TMA) blocks were created from 152 cases of DLBCL, 142 of which had been successfully evaluated by cDNA microarray (75 GCB, 41 ABC, and 26 type 3). Sections were stained with antibodies to CD10, bcl-6, MUM1, FOXP1, cyclin D2, and bcl-2. Expression of bcl-6 (P <.001) or CD10 (P =.019) was associated with better overall survival (OS), whereas expression of MUM1 (P =.009) or cyclin D2 (P <.001) was associated with worse OS. Cases were subclassified using CD10, bcl-6, and MUM1 expression, and 64 cases (42%) were considered GCB and 88 cases (58%) non-GCB. The 5-year OS for the GCB group was 76% compared with only 34% for the non-GCB group (P <.001), which is similar to that reported using the cDNA microarray. Bcl-2 and cyclin D2 were adverse predictors in the non-GCB group. In multivariate analysis, a high International Prognostic Index score (3-5) and the non-GCB phenotype were independent adverse predictors (P <.0001). In summary, immunostains can be used to determine the GCB and non-GCB subtypes of DLBCL and predict survival similar to the cDNA microarray. |
| first_indexed | 2024-03-06T23:23:41Z |
| format | Journal article |
| id | oxford-uuid:69a62161-7141-49b0-8d74-d9b84cc11850 |
| institution | University of Oxford |
| language | English |
| last_indexed | 2024-03-06T23:23:41Z |
| publishDate | 2004 |
| record_format | dspace |
| spelling | oxford-uuid:69a62161-7141-49b0-8d74-d9b84cc118502022-03-26T18:52:21ZConfirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray.Journal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:69a62161-7141-49b0-8d74-d9b84cc11850EnglishSymplectic Elements at Oxford2004Hans, CWeisenburger, DGreiner, TGascoyne, RDelabie, JOtt, GMüller-Hermelink, HCampo, EBraziel, RJaffe, EPan, ZFarinha, PSmith, LFalini, BBanham, ARosenwald, AStaudt, LConnors, JArmitage, JChan, WDiffuse large B-cell lymphoma (DLBCL) can be divided into prognostically important subgroups with germinal center B-cell-like (GCB), activated B-cell-like (ABC), and type 3 gene expression profiles using a cDNA microarray. Tissue microarray (TMA) blocks were created from 152 cases of DLBCL, 142 of which had been successfully evaluated by cDNA microarray (75 GCB, 41 ABC, and 26 type 3). Sections were stained with antibodies to CD10, bcl-6, MUM1, FOXP1, cyclin D2, and bcl-2. Expression of bcl-6 (P <.001) or CD10 (P =.019) was associated with better overall survival (OS), whereas expression of MUM1 (P =.009) or cyclin D2 (P <.001) was associated with worse OS. Cases were subclassified using CD10, bcl-6, and MUM1 expression, and 64 cases (42%) were considered GCB and 88 cases (58%) non-GCB. The 5-year OS for the GCB group was 76% compared with only 34% for the non-GCB group (P <.001), which is similar to that reported using the cDNA microarray. Bcl-2 and cyclin D2 were adverse predictors in the non-GCB group. In multivariate analysis, a high International Prognostic Index score (3-5) and the non-GCB phenotype were independent adverse predictors (P <.0001). In summary, immunostains can be used to determine the GCB and non-GCB subtypes of DLBCL and predict survival similar to the cDNA microarray. |
| spellingShingle | Hans, C Weisenburger, D Greiner, T Gascoyne, R Delabie, J Ott, G Müller-Hermelink, H Campo, E Braziel, R Jaffe, E Pan, Z Farinha, P Smith, L Falini, B Banham, A Rosenwald, A Staudt, L Connors, J Armitage, J Chan, W Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. |
| title | Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. |
| title_full | Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. |
| title_fullStr | Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. |
| title_full_unstemmed | Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. |
| title_short | Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. |
| title_sort | confirmation of the molecular classification of diffuse large b cell lymphoma by immunohistochemistry using a tissue microarray |
| work_keys_str_mv | AT hansc confirmationofthemolecularclassificationofdiffuselargebcelllymphomabyimmunohistochemistryusingatissuemicroarray AT weisenburgerd confirmationofthemolecularclassificationofdiffuselargebcelllymphomabyimmunohistochemistryusingatissuemicroarray AT greinert confirmationofthemolecularclassificationofdiffuselargebcelllymphomabyimmunohistochemistryusingatissuemicroarray AT gascoyner confirmationofthemolecularclassificationofdiffuselargebcelllymphomabyimmunohistochemistryusingatissuemicroarray AT delabiej confirmationofthemolecularclassificationofdiffuselargebcelllymphomabyimmunohistochemistryusingatissuemicroarray AT ottg confirmationofthemolecularclassificationofdiffuselargebcelllymphomabyimmunohistochemistryusingatissuemicroarray AT mullerhermelinkh confirmationofthemolecularclassificationofdiffuselargebcelllymphomabyimmunohistochemistryusingatissuemicroarray AT campoe confirmationofthemolecularclassificationofdiffuselargebcelllymphomabyimmunohistochemistryusingatissuemicroarray AT brazielr confirmationofthemolecularclassificationofdiffuselargebcelllymphomabyimmunohistochemistryusingatissuemicroarray AT jaffee confirmationofthemolecularclassificationofdiffuselargebcelllymphomabyimmunohistochemistryusingatissuemicroarray AT panz confirmationofthemolecularclassificationofdiffuselargebcelllymphomabyimmunohistochemistryusingatissuemicroarray AT farinhap confirmationofthemolecularclassificationofdiffuselargebcelllymphomabyimmunohistochemistryusingatissuemicroarray AT smithl confirmationofthemolecularclassificationofdiffuselargebcelllymphomabyimmunohistochemistryusingatissuemicroarray AT falinib confirmationofthemolecularclassificationofdiffuselargebcelllymphomabyimmunohistochemistryusingatissuemicroarray AT banhama confirmationofthemolecularclassificationofdiffuselargebcelllymphomabyimmunohistochemistryusingatissuemicroarray AT rosenwalda confirmationofthemolecularclassificationofdiffuselargebcelllymphomabyimmunohistochemistryusingatissuemicroarray AT staudtl confirmationofthemolecularclassificationofdiffuselargebcelllymphomabyimmunohistochemistryusingatissuemicroarray AT connorsj confirmationofthemolecularclassificationofdiffuselargebcelllymphomabyimmunohistochemistryusingatissuemicroarray AT armitagej confirmationofthemolecularclassificationofdiffuselargebcelllymphomabyimmunohistochemistryusingatissuemicroarray AT chanw confirmationofthemolecularclassificationofdiffuselargebcelllymphomabyimmunohistochemistryusingatissuemicroarray |